Drug Type Small molecule drug |
Synonyms AZD 9056, AZD9056, MP-118 + [1] |
Target |
Action antagonists |
Mechanism P2X7 receptor antagonists(P2X purinoceptor 7 antagonists) |
Therapeutic Areas |
Active Indication- |
Inactive Indication |
Originator Organization |
Active Organization- |
Inactive Organization |
Drug Highest PhaseDiscontinuedPhase 2 |
First Approval Date- |
Regulation- |
Molecular FormulaC24H35ClN2O2 |
InChIKeyHSQAARMBHJCUOK-UHFFFAOYSA-N |
CAS Registry345304-65-6 |
KEGG | Wiki | ATC | Drug Bank |
---|---|---|---|
- | - | - |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Rheumatoid Arthritis | Phase 2 | United States | 01 Aug 2007 | |
Rheumatoid Arthritis | Phase 2 | Argentina | 01 Aug 2007 | |
Rheumatoid Arthritis | Phase 2 | Australia | 01 Aug 2007 | |
Rheumatoid Arthritis | Phase 2 | Belgium | 01 Aug 2007 | |
Rheumatoid Arthritis | Phase 2 | Canada | 01 Aug 2007 | |
Rheumatoid Arthritis | Phase 2 | Czechia | 01 Aug 2007 | |
Rheumatoid Arthritis | Phase 2 | France | 01 Aug 2007 | |
Rheumatoid Arthritis | Phase 2 | Mexico | 01 Aug 2007 | |
Rheumatoid Arthritis | Phase 2 | Poland | 01 Aug 2007 | |
Rheumatoid Arthritis | Phase 2 | Romania | 01 Aug 2007 |
Phase 2 | 383 | pjigashezw(pqrfytudab) = jnyhmdqpxd ffvuemrpox (qnwomvpbly ) | Negative | 01 Oct 2012 | |||
Placebo | pjigashezw(pqrfytudab) = ybuwbhdlqz ffvuemrpox (qnwomvpbly ) | ||||||
Phase 2 | 385 | (AZD9056 50 mg) | vgwvhsisbu = nqfaqnfhyh acidlttmmn (pwxiyzqmik, gulcxlhgnx - hknljhytua) View more | - | 04 Oct 2010 | ||
(AZD9056 100 mg) | vgwvhsisbu = axcuxrqqvd acidlttmmn (pwxiyzqmik, qvkzhjnmhs - vefmdneqjo) View more | ||||||
Phase 2 | 75 | AZD9056 100 mg | wyqdgdlxwk(aeficlpbyy) = reocqdguxc zfwkmeywvy (bwxdxxybgs ) | Positive | 10 Jun 2009 | ||
wyqdgdlxwk(aeficlpbyy) = gydwarzfcz zfwkmeywvy (bwxdxxybgs ) |